Composition and application thereof in scalp conditioning, hair loss prevention and hair growth

Abstract

The invention relates to a composition and application thereof in scalp conditioning, hair loss prevention and hair growth, and the composition is prepared from the following components in parts by weight: 0.00001 to 10 parts of thiotaurine, 0.00001 to 30 parts of nicotinamide and 0.00001 to 10 parts of glycine-histidine-lysine-copper. The composition can optimize scalp cell energy supply so as to promote synthesis of hair follicle growth factors, reduce release of hair follicle growth inhibition factors and achieve the effects of scalp care, hair loss prevention and hair growth.

Description

[0001] Related applications

[0002] This application claims priority to Chinese patent application No. 2024118864435, filed on December 20, 2024, entitled “Composition and its use in scalp conditioning and hair loss prevention and growth”, the entire text of which is hereby incorporated by reference. Technical Field

[0003] The present application relates to the technical field of cosmetics, and in particular to a composition and its application in scalp conditioning and hair loss prevention and growth. Background Art

[0004] With the accelerating pace and frequency of life, scalp and hair loss problems are becoming more and more common, and are increasingly affecting younger people. The public, especially young people, are paying more and more attention to these issues. Hair loss is a complex issue, caused by both internal factors (such as genetics) and external factors (such as environmental stimuli) such as scalp inflammation, aging, and endogenous hormone changes induced by aging.

[0005] Androgenic alopecia (AGA) is the most common type of hair loss. It typically occurs in young and middle-aged men and has a strong family history. Patients are genetically predisposed and develop the disease when exposed to androgens. Human experimental models have demonstrated that the male hormone testosterone plays a crucial role in the pathogenesis of AGA. Testosterone, the primary androgen in the body, is converted to highly active dihydrotestosterone (DHT) by 5-α-reductase. DHT triggers the transformation of terminal hair into vellus hair, inducing the synthesis and release of inhibitory factors in dermal papilla cells, which in turn inhibits follicular epithelial cells, thereby affecting hair growth. DHT promotes the transition of hair follicles from the anagen phase to the catagen phase, causing hair loss. Research has found that each adult human hair follicle relies on its own intrinsic growth-promoting signals to maintain normal follicle and hair growth. When the inhibitory signals within the follicle become stronger than the growth-promoting signals, the follicle degenerates. This suggests that maintaining the growth environment of individual hair follicles is crucial for preventing hair loss. By regulating the cytokine environment of hair follicles: promoting the production of hair follicle growth factors (such as VEGF), reducing the production of inhibitory factors (such as TGF-β1 / β2, DKK-1), it helps maintain the normal growth phase of hair follicles, thereby playing a role in preventing hair loss, strengthening hair and promoting hair growth.

[0006] Other studies have shown that dermal papilla cells extracted from AGA patients are prone to premature aging in vitro and are more susceptible to environmental stimuli, especially oxidative stress. Under oxidative stress conditions, dermal papilla cells undergo premature aging, causing a decrease in energy metabolism, and the growth of hair follicles and hair cannot be effectively supported, causing hair loss. At the same time, oxidative stress causes dermal papilla cells to proliferate rapidly and consume and accelerate aging. It has a synergistic effect with dihydrotestosterone. When both are present, the synthesis and secretion of TGF-β increases significantly, thereby inhibiting the growth of hair follicles and hair. Therefore, many factors that increase cellular oxidative stress, including skin inflammation, drinking, smoking, and ultraviolet radiation, can induce scalp aging and hair loss.

[0007] The catechin 7-O-β-D-furanose glycoside compound has been reported to inhibit the conversion of testosterone into dihydrotestosterone (DHT) in human hair follicle dermal papilla cells via 5α-reductase, thereby suppressing dermal papilla cell apoptosis caused by oxidative stress. It is therefore a promising active ingredient for the treatment, prevention, or improvement of hair loss. Most products on the market prevent hair loss and promote hair growth by inhibiting 5α-reductase and improving scalp nutrient supply pathways. However, the mechanism of AGA is primarily driven by internal and external factors: 1. Cellular senescence and decreased cellular energy metabolism; 2. The synergistic inhibition of the hair follicle growth cycle by cellular oxidative stress and DHT is the primary factor. No effective combination exists that comprehensively targets these pathways. Summary of the Invention

[0008] Based on this, one embodiment of the present application provides a method for maintaining the redox balance of scalp cells, relieving oxidative stress and the synergistic hair loss-promoting effect of dihydrotestosterone, and the composition can optimize the energy supply of scalp cells.

[0009] The technical solution includes:

[0010] A composition comprises the following components in parts by weight: 0.00001-10 parts of thiotaurine, 0.00001-30 parts of nicotinamide and 0.00001-10 parts of glycine-histidine-lysine-copper.

[0011] In one embodiment, the composition comprises the following components in parts by weight: 0.3-1 parts of thiotaurine, 1-2.5 parts of nicotinamide, and 0.2-1 parts of glycine-histidine-lysine-copper; preferably, 0.4-0.7 parts of thiotaurine, 1.3-2 parts of nicotinamide, and 0.3-0.8 parts of glycine-histidine-lysine-copper; more preferably, 0.4-0.6 parts of thiotaurine, 1.4-1.7 parts of nicotinamide, and 0.4-0.6 parts of glycine-histidine-lysine-copper.

[0012] In one embodiment, a preservative is also included.

[0013] Optionally, the preservative includes one or more of phenoxyethanol, methylparaben, ethylparaben, propylparaben, methylisothiazolinone, p-hydroxyacetophenone, polyol preservatives, organic acid preservatives and cationic preservatives.

[0014] Optionally, the polyol preservative includes one or more of glycerol, propylene glycol, butylene glycol, 1,2-pentanediol, caprylyl glycol, ethylene glycol and 1,2-hexanediol.

[0015] Optionally, the organic acid preservative includes one or more of caprylhydroxamic acid, sorbic acid and benzoic acid.

[0016] Optionally, the cationic preservative includes one or more of quaternary ammonium salts and hexamidine di(hydroxyethylsulfonic acid) salt.

[0017] Optionally, the composition comprises 0.1-20 parts of the preservative by weight.

[0018] The preparation method of the composition comprises the step of mixing the thiotaurine, the nicotinamide and the glycine-histidine-lysine-copper.

[0019] The composition is used in preparing a product for promoting proliferation of dermal papilla cells.

[0020] The composition is used in preparing a product for promoting the expression or activity of hair follicle growth factor.

[0021] Optionally, the hair follicle growth factor comprises VEGF.

[0022] The composition is used in preparing a product for inhibiting the expression or activity of hair follicle inhibitory factor.

[0023] Optionally, the hair follicle inhibitory factor includes TGF-β and / or DKK1.

[0024] The composition is used in preparing a product for promoting the expression or activity of hair follicle cyclin β-catenin.

[0025] The composition is used in preparing products for scalp care and / or hair loss prevention and growth.

[0026] A product comprising the composition.

[0027] Optionally, the product further comprises auxiliary materials acceptable for toiletries.

[0028] Optionally, the product includes toiletries.

[0029] Compared with traditional technologies, this application has the following beneficial effects:

[0030] The present application provides a composition that can maintain the redox balance of scalp cells, relieve oxidative stress and the synergistic hair loss-promoting effects of dihydrotestosterone, and optimize the energy supply of scalp cells, thereby promoting the synthesis of hair follicle growth factors and reducing the release of hair follicle growth inhibitory factors, thereby playing a role in scalp care and hair loss prevention and growth. The composition has broad application prospects in scalp care, hair loss prevention, hair strengthening and hair growth products. DETAILED DESCRIPTION

[0031] To make the above-mentioned objects, features, and advantages of the present application more clearly understood, the specific embodiments of the present application are described in detail below. The following description sets forth many specific details to facilitate a full understanding of the present application. However, the present application can be implemented in many other ways than those described herein, and those skilled in the art can make similar modifications without violating the scope of the present application. Therefore, the present application is not limited to the specific embodiments disclosed below.

[0032] Unless otherwise defined, all technical and scientific terms used herein have the same meaning as those commonly understood by those skilled in the art to which this application pertains. The terms used herein in the specification of this application are for the purpose of describing specific embodiments only and are not intended to limit this application.

[0033] As used herein, the term "and / or" includes any and all combinations of one or more of the associated listed items.

[0034] In this application, unless otherwise specified, "one or more" refers to any one of the listed items or any combination of the listed items. Similarly, "one or more" and other similar expressions that refer to "one or more" are also understood in the same way unless otherwise specified.

[0035] In this application, the terms "optionally," "optional," and "optional" mean optional, that is, they refer to either option selected from the two parallel options of "yes" or "no." If multiple "options" appear in a technical solution, unless otherwise specified and there are no contradictions or mutual constraints, each "optional" is independent. Unless otherwise specified, the descriptions "optionally include," "optionally include," etc. in this application, taking "optionally include" as an example, mean "may include or not include."

[0036] In this application, when referring to a numerical interval (i.e., a numerical range), unless otherwise specified, the distribution of the optional numerical values in the numerical interval is considered to be continuous and includes the two numerical endpoints (i.e., the minimum and maximum values) of the numerical interval, and each numerical value between the two numerical endpoints. Unless otherwise specified, when a numerical interval only refers to an integer in the numerical interval, including the two endpoint integers of the numerical range and each integer between the two endpoints, is equivalent to directly enumerating each integer. When multiple numerical ranges are provided to describe a feature or characteristic, these numerical ranges can be merged. In other words, unless otherwise specified, the numerical range disclosed herein should be understood to include any and all subranges included therein. The "numerical value" in the numerical interval can be any quantitative value, such as a number, a percentage, a ratio, etc. "Numerical interval" allows broadly including numerical interval types such as percentage intervals, ratio intervals, and ratio intervals.

[0037] In this article, the "hair follicle growth cycle" can be divided into three stages: the growth phase (2 to 7 years), the catagen phase (approximately 3 weeks), and the resting phase (approximately 3 months). The physiological characteristics of the growth phase include: the growth phase is the period of most active hair follicle growth. After hair follicle stem cells are activated, they begin to rapidly proliferate and differentiate. During this phase, the hair follicles penetrate deep into the dermis and subcutaneous tissue of the skin. The dermal papilla cells are very active and secrete a variety of growth factors, such as vascular endothelial growth factor (VEGF). These growth factors stimulate the continuous division of hair follicle cells, causing hair to grow outward from the base of the follicle. For example, human scalp hair can grow approximately 0.3-0.4 mm per day during the growth phase. At the same time, the inner and outer root sheath cells surround the matrix cells, providing support and nutrient delivery channels for hair growth. During this period, the hair follicles have a rich blood supply, thanks to the angiogenesis induced by the dermal papilla cells, which brings a large amount of oxygen and nutrients to the hair growth. Physiological Characteristics of the Catagen Phase: When a hair follicle enters the catagen phase, its growth rate slows significantly. This transitional phase occurs. Dermal papilla cells become less active, secreting fewer growth factors, and the proliferation and differentiation of hair follicle stem cells cease. The lower portion of the follicle begins to degenerate, and cell apoptosis increases significantly. The outer root sheath of the follicle gradually shrinks, weakening its connection with the dermal papilla cells. Hair growth ceases, and the bulb begins to shift upward, gradually approaching the skin surface. Morphologically, the hair follicle gradually decreases in size during this phase, seemingly adjusting itself in preparation for the telogen phase. Physiological Characteristics of the Telogen Phase: During the telogen phase, the hair follicle remains relatively quiescent. The base of the follicle shrinks, and the hair lies dormant within the follicle, no longer growing. The blood supply to the follicle is also reduced, and the dermal papilla cells are inactive, maintaining only basic cellular metabolism. The stem cells of the hair follicle lie dormant, awaiting the next growth signal. At the end of the resting phase, a new hair follicle cycle may begin, and the hair follicle stem cells will be reactivated under the stimulation of various growth factors, starting the next round of growth.

[0038] In this article, "VEGF" (vascular endothelial growth factor) is a highly specific vascular endothelial cell growth factor that plays a key role in numerous physiological processes in the body. It stimulates the formation of new blood vessels primarily by promoting the proliferation, migration, and lumen formation of endothelial cells. In hair follicles, VEGF is primarily secreted by dermal papilla cells. During the growth phase of hair follicles, VEGF levels are relatively high. Its expression level and activity are extremely important for the normal growth, development, and repair of hair follicles.

[0039] In this article, "TGF-β2," or transforming growth factor-β2, a member of the TGF-β superfamily, is a multifunctional cytokine that plays a crucial role in regulating hair follicle growth. It can inhibit the proliferation and differentiation of hair follicle stem cells. During the catagen phase of the hair follicle cycle, TGF-β2 expression levels increase. This indirectly inhibits hair follicle growth by suppressing the secretion of growth factors by dermal papilla cells. Furthermore, TGF-β2 may affect the synthesis and secretion of extracellular matrix components by dermal papilla cells, altering the microenvironment surrounding these cells and, consequently, affecting the physiological state of the hair follicle.

[0040] In this article, "DKK1" is a secreted protein that affects hair follicle growth primarily by regulating the Wnt signaling pathway. The Wnt signaling pathway is crucial in initiating and maintaining hair follicle growth. DKK-1 can bind to Wnt receptors, thereby blocking Wnt signals and inhibiting the activation and proliferation of hair follicle stem cells. In some hair loss diseases, such as androgenic alopecia, DKK-1 expression levels are elevated, which may be one of the causes of hair follicle atrophy and hair thinning.

[0041] In this article, "β-catenin" refers to a protein that is strongly expressed during the growth phase of hair follicles and promotes the maintenance of the hair follicle growth cycle. The proliferation and differentiation of dermal papilla cells are also critical for the normal function of hair follicles. β-catenin regulates the proliferation of dermal papilla cells. β-catenin can induce dermal papilla cells to differentiate in a direction that is beneficial to hair follicle growth. It does this by regulating the activity of certain transcription factors, enabling dermal papilla cells to better perform their role in hair follicle growth.

[0042] This application combines multiple active ingredients with different target pathways to screen out an active composition for scalp care for hair loss and hair growth problems, including thiotaurine, nicotinamide, and glycine-histidine-lysine-copper. The thiotaurine in the active combination is converted into hypotaurine in the body, which can promote the production of reduced glutathione. Nicotinamide (vitamin B3) is a component of coenzyme II and maintains the NADP+ / NADPH system in the body. These two ensure the body's reducing ability, reduce excessive oxidative stress damage induced by internal and external environments, relieve the synergistic effect of oxidative stress and DHT on hair loss, and inhibit the production and secretion of TGF-β. At the same time, taurine produced by the metabolism of thiotaurine can promote cellular energy metabolism, and nicotinamide, as a component of coenzyme I, promotes the production of cellular ATP. Both also promote and maintain the energy supply of hair follicle cells. The glycine-histidine-lysine-copper (GHK-Cu tripeptide) in the active combination has a synergistic effect when combined with thiotaurine and nicotinamide, significantly improving the synthesis of hair follicle growth factor compared to their use alone.

[0043] One embodiment of the present application provides a composition comprising the following components, in parts by weight: 0.00001-10 parts of thiotaurine, 0.00001-30 parts of nicotinamide, and 0.00001-10 parts of glycine-histidine-lysine-copper.

[0044] The composition can stabilize the skin environment, maintain the balance of cellular oxidative stress and promote the growth of hair follicles and hair. The composition can achieve the effects of hair strengthening, hair loss prevention and hair growth.

[0045] The composition can effectively promote the synthesis of hair follicle growth factor and reduce the synthesis of hair follicle inhibitory factor through the combination of three specific target efficacy substances. In addition, thiotaurine and niacinamide (vitamin B3) have a synergistic effect with glycine-histidine-lysine-copper (GHK-Cu tripeptide), which can significantly improve the effect of glycine-histidine-lysine-copper (GHK-Cu tripeptide) when used alone.

[0046] In a specific example, the following components are included, in parts by weight: 0.3-1 parts of thiotaurine; 1-2.5 parts of nicotinamide (vitamin B3); 0.2-1 parts of glycine-histidine-lysine-copper (GHK-Cu tripeptide); preferably, 0.4-0.7 parts of thiotaurine, 1.3-2 parts of nicotinamide and 0.3-0.8 parts of glycine-histidine-lysine-copper; more preferably, 0.4-0.6 parts of thiotaurine, 1.4-1.7 parts of nicotinamide and 0.4-0.6 parts of glycine-histidine-lysine-copper.

[0047] In a specific example, the amount of thiotaurine in the composition can be 0.3 parts, 0.4 parts, 0.5 parts, 0.6 parts, 0.7 parts, 0.8 parts, 0.9 parts, 1 part, or a range between any two of the above values in parts by weight.

[0048] In a specific example, the amount of niacinamide in the composition can be 1 part, 1.2 parts, 1.4 parts, 1.5 parts, 1.6 parts, 1.8 parts, 2.0 parts, 2.2 parts, 2.5 parts, or a range between any two of the above values, in parts by weight.

[0049] In a specific example, the glycine-histidine-lysine-copper content in the composition can be selected as 0.2 parts, 0.3 parts, 0.4 parts, 0.5 parts, 0.6 parts, 0.7 parts, 0.8 parts, 0.9 parts, 1 part, or a range between any two of the above values in parts by weight.

[0050] In one embodiment, the composition further comprises a preservative.

[0051] In a specific example, the preservatives include conventional preservative systems, polyol preservative systems, organic acid preservative systems, and cationic preservative systems.

[0052] In a specific example, the conventional preservative system includes, but is not limited to, one or more of phenoxyethanol, methylparaben, ethylparaben, propylparaben, methylisothiazolinone, and p-hydroxyacetophenone.

[0053] In a specific example, the polyol preservative system includes one or more of glycerol, propylene glycol, butylene glycol, 1,2-pentanediol, caprylyl glycol, ethylene glycol, and 1,2-hexanediol.

[0054] In a specific example, the organic acid preservative system includes one or more of octanoylhydroxamic acid, sorbic acid, and benzoic acid.

[0055] In a specific example, the cationic preservative system includes one or more of quaternary ammonium salts and hexamidine di-isethionate.

[0056] In one specific example, the composition includes 0.1-20 parts by weight of a preservative, optionally 0.1, 0.5, 1, 5, 10, 15, or 20 parts. The inventors of this application are aware of the restrictions on the amount of preservatives in the National Cosmetic Safety Technical Specifications and other relevant laws and regulations. The amount of preservative used in this specific embodiment can control the preservative content of the product within the above-mentioned prescribed addition range.

[0057] One embodiment of the present application further provides a method for preparing the composition, comprising the step of mixing the thiotaurine, the nicotinamide, and the glycine-histidine-lysine-copper.

[0058] One embodiment of the present application also provides use of the composition in preparing a product for promoting dermal papilla cell proliferation.

[0059] One embodiment of the present application further provides use of the composition in preparing a product that promotes the expression or activity of hair follicle growth factor.

[0060] In one specific example, the hair follicle growth factor includes VEGF.

[0061] One embodiment of the present application further provides use of the composition in preparing a product for inhibiting the expression or activity of hair follicle inhibitory factor.

[0062] In a specific example, the hair follicle inhibitory factor includes TGF-β and / or DKK1; optionally, the TGF-β includes TGF-β2.

[0063] One embodiment of the present application further provides use of the composition in preparing a product for promoting the expression or activity of the hair follicle cyclin β-catenin.

[0064] One embodiment of the present application also provides the use of the composition in preparing scalp care and hair loss prevention and growth products.

[0065] One embodiment of the present application further provides a hair care or scalp care product, comprising a composition and, optionally, an auxiliary material. Optionally, the auxiliary material is a cosmetically acceptable auxiliary material.

[0066] The embodiments of the present application will be described in detail below with reference to the examples. It should be understood that these examples are intended to illustrate the present application only and are not intended to limit the scope of the present application. The experimental methods for which specific conditions are not specified in the following examples are preferably referred to the guidance provided in the present application, and can also be based on the experimental manuals or conventional conditions in this area, or according to the conditions recommended by the manufacturer, or with reference to experimental methods known in the art.

[0067] In the following specific examples, the measured parameters of raw material components may have slight deviations within the range of weighing accuracy unless otherwise specified. For temperature and time parameters, acceptable deviations caused by instrument testing accuracy or operational accuracy are allowed.

[0068] In the following examples, thiotaurine CAS#: 2937-54-4, nicotinamide CAS#: 98-92-0, and the GHK-Cu tripeptide structural formula are:

[0069] Example 1

[0070] This embodiment provides a composition comprising the following raw materials in parts by weight: 0.3 parts of thiotaurine, 1 part of niacinamide (vitamin B3), 0.5 parts of glycine-histidine-lysine-copper (GHK-Cu tripeptide), 0.1 parts of phenoxyethanol, and the balance being purified water. The total weight of the above raw materials is 100 parts.

[0071] Example 2

[0072] This embodiment provides a composition comprising the following raw materials in parts by weight: 0.5 parts of thiotaurine, 1.5 parts of niacinamide (vitamin B3), 0.5 parts of glycine-histidine-lysine-copper (GHK-Cu tripeptide), 0.1 parts of phenoxyethanol, and the balance being purified water. The total weight of the above raw materials is 100 parts.

[0073] Example 3

[0074] This embodiment provides a composition comprising the following raw materials in parts by weight: 1 part of thiotaurine, 2.5 parts of niacinamide (vitamin B3), 0.5 parts of glycine-histidine-lysine-copper (GHK-Cu tripeptide), 0.1 parts of phenoxyethanol, and the balance being purified water. The total weight of the above raw materials is 100 parts.

[0075] Example 4

[0076] This embodiment provides a composition comprising the following raw materials in parts by weight: 1 part of thiotaurine, 2.5 parts of niacinamide (vitamin B3), 1 part of glycine-histidine-lysine-copper (GHK-Cu tripeptide), 0.1 part of phenoxyethanol, and the balance being purified water. The total weight of the above raw materials is 100 parts.

[0077] Example 5

[0078] This embodiment provides a composition comprising the following raw materials in parts by weight: 10 parts of thiotaurine, 30 parts of niacinamide (vitamin B3), 10 parts of glycine-histidine-lysine-copper (GHK-Cu tripeptide), 20 parts of glycerol, and the balance being purified water. The total weight of the above raw materials is 100 parts.

[0079] Example 6

[0080] This embodiment provides a composition comprising the following raw materials in parts by weight: 0.00001 parts of thiotaurine, 0.00001 parts of niacinamide (vitamin B3), 0.00001 parts of glycine-histidine-lysine-copper (GHK-Cu tripeptide), 1 part of sorbic acid, and the balance being purified water. The total weight of the above raw materials is 100 parts.

[0081] Example 7

[0082] This embodiment provides a composition comprising the following raw materials in parts by weight: 5 parts of thiotaurine, 5 parts of niacinamide (vitamin B3), 5 parts of glycine-histidine-lysine-copper (GHK-Cu tripeptide), 0.1 parts of phenoxyethanol, and the balance being purified water. The total weight of the above raw materials is 100 parts.

[0083] Comparative Example 1

[0084] The difference from Example 2 is that the preparation method is composed of the following raw materials in parts by weight: 2.5 parts of glycine-histidine-lysine-copper (GHK-Cu tripeptide), 0.1 parts of phenoxyethanol, and the balance is purified water, and the total weight of the above raw materials is 100 parts.

[0085] Comparative Example 2

[0086] The difference from Example 2 is that the preparation is composed of the following raw materials in parts by weight: 2.5 parts of thiotaurine, 0.1 parts of phenoxyethanol, and the balance is purified water, and the total weight of the above raw materials is 100 parts.

[0087] Comparative Example 3

[0088] The difference from Example 2 is that the preparation is composed of the following raw materials in parts by weight: 2.5 parts of niacinamide, 0.1 parts of phenoxyethanol, and the balance is purified water, and the total weight of the above raw materials is 100 parts.

[0089] Comparative Example 4

[0090] This comparative example provides a composition consisting of the following raw materials in parts by weight: 0.5 parts of glutathione, 1.5 parts of niacinamide (vitamin B3), 0.5 parts of glycine-histidine-lysine-copper (GHK-Cu tripeptide), 0.1 parts of phenoxyethanol, and the balance being purified water. The sum of the parts by weight of the above raw materials is 100 parts.

[0091] Comparative Example 5

[0092] This comparative example provides a composition consisting of the following raw materials in parts by weight: 0.5 parts of thiotaurine, 1.5 parts of inositol, 0.5 parts of glycine-histidine-lysine-copper (GHK-Cu tripeptide), 0.1 parts of phenoxyethanol, and the balance being purified water. The sum of the parts by weight of the above raw materials is 100 parts.

[0093] Comparative Example 6

[0094] This comparative example provides a composition consisting of the following raw materials in parts by weight: 0.5 parts of thiotaurine, 1.5 parts of niacinamide (vitamin B3), 0.5 parts of biotin tripeptide-1, 0.1 parts of phenoxyethanol, and the balance being purified water. The total weight of the above raw materials is 100 parts.

[0095] Experimental Example 1

[0096] The composition samples of Examples 1-7 and Comparative Examples 1-6 were co-cultured with dermal papilla cells (Guangdong Boxi Biotechnology Co., Ltd.), with the volume fraction of the composition in the culture system being 1.25%. After co-culture, cell growth was measured (MTT assay), and then the hair follicle regulatory factors and β-catenin were measured. The determination of hair follicle regulatory factors included measuring the content of hair follicle growth factor VEGF and the gene expression of hair follicle inhibitory factors DKK1 and TGF-β2. The determination of β-catenin included measuring the gene expression of β-catenin.

[0097] The specific steps are as follows:

[0098] 1) Inoculation: 3.0×10 5 Dermal papilla cells were seeded into 6-well plates at a seeding density of 100 cells / well and incubated in a (37°C, CO2, 2% O2) incubator overnight.

[0099] 2) DHT stimulation and drug administration: According to the test group, when the cell plating rate in the 6-well plate reaches about 40-60%, drug administration is performed, and the group with DHT stimulation conditions is subjected to DHT stimulation. After completion, the cells are placed in an incubator (37°C, CO2, 21% O2) for 24 hours.

[0100] 3) ELISA assay: After 24 h of incubation, the cell supernatant was collected and the VEGF content was detected and analyzed according to the operating instructions of the ELISA kit.

[0101] 4) Gene expression detection: After 24 hours of incubation, the cell supernatant was collected and washed twice with 1 mL / well PBS. 1 mL RNAisoPlus was added to each well and the cells were lysed by pipetting. The samples were collected. RNA was extracted and reverse transcribed to cDNA. Fluorescence quantitative PCR was performed using 2 -△△CT Method to calculate the results.

[0102] 5) Statistical Analysis: Results are expressed as mean ± SD. Comparisons between groups were performed using the t-test. All statistical analyses were two-tailed. P < 0.05 was considered a significant difference, and P < 0.01 was considered a highly significant difference.

[0103] 6) The test design of each embodiment and comparative example sample is shown in Table 1. The blank control is not treated, the negative control is stimulated with DHT, the positive control is added with minoxidil and DHT, and the embodiments and comparative examples are treated with the sample and DHT, respectively.

[0104] Table 1 Dermal papilla cell test design

[0105]

[0106] The VEGF concentration in the sample groups of Examples 1-7 was significantly higher than that in the negative control. Compared with the examples, the effects of using the three components in equal amounts alone in Comparative Examples 1-3 were lower than those of using them in combination. The effects of combining the three components in pairs and matching the same type of raw materials in Comparative Examples 4-6 were also lower than the effects of combining thiotaurine, nicotinamide, and GHK-Cu tripeptide, indicating that the combination of thiotaurine, nicotinamide, and GHK-Cu tripeptide has a synergistic effect. The VEGF content test results of the sample groups are shown in Table 2.

[0107] Table 2

[0108] Group Average concentration (pg / ml) SD P-value Improvement rate BC 2533.22 6.87 / / NC 2224.63 27.88 0.000## / PC 2491.11 93.39 0.009** / Example 1 2533.22 6.87 0.007** 13.87％ Example 2 2741.14 102.31 0.001** 23.22％ Example 3 2577.54 63.93 0.001** 15.86％ Example 4 2621.27 48.18 0.001** 17.83％ Example 5 / / / / Example 6 / / / / Example 7 / / / / Comparative Example 1 2308.23 17.21 0.001** 3.75％ Comparative Example 2 2235.63 39.88 0.715 0.49％ Comparative Example 3 2271.57 41.32 0.201 2.11％ Comparative Example 4 2451.64 35.13 0.003** 10.20％ Comparative Example 5 2417.33 37.15 0.006** 8.66％ Comparative Example 6 2399.12 28.09 0.004** 7.84％

[0109] Note: When the t-test method was used for statistical analysis, compared with the BC group, the significance was indicated by #, P-value < 0.05 was indicated by #, and P-value < 0.01 was indicated by ##; compared with the NC group, the significance was indicated by *, P-value < 0.05 was indicated by *, and P-value < 0.01 was indicated by **.

[0110] The expression of TGF-β2 gene in the sample groups of Examples 1-7 was significantly lower than that in the negative control. Compared with the examples, the effects of using the three components in equal amounts alone in Comparative Examples 1-3 were lower than those of using them in combination. The effects of using the three components in pairs in Comparative Examples 4-6 and matching the same type of raw materials were also lower than the effects of the combination of thiotaurine, nicotinamide, and GHK-Cu tripeptide, indicating that the combination of thiotaurine, nicotinamide, and GHK-Cu tripeptide has a synergistic effect. The results of the TGF-β2 content test of the sample groups are shown in Table 3.

[0111] Table 3

[0112]

[0113]

[0114] Note: Use 2 -△△CT Methods The results were calculated and statistically analyzed using the t-test method. The mRNA amplification fold of the BC group was normalized. Compared with the BC group, significance was indicated by #, P-value < 0.05 was indicated by #, and P-value < 0.01 was indicated by ##. Compared with the NC group, significance was indicated by *, P-value < 0.05 was indicated by *, and P-value < 0.01 was indicated by **.

[0115] At the same time, we also measured the DKK1 expression and β-catenin gene expression of samples selected from some embodiments and comparative examples.

[0116] Compared to the negative control, the sample groups of Examples and Comparative Examples significantly downregulated DKK1 expression in dermal papilla cells. Compared to Comparative Example 1, the downregulation ratio of the sample groups of Examples 1-3 was more significant. The results of DKK1 gene expression detection in some sample groups are shown in Table 4.

[0117] Table 4

[0118] Group Mean SD P-value Reduction rate BC 1.00 0.08 / / NC 1.45 0.11 0.005### / PC 1.01 0.07 0.005** / Example 1 0.90 0.03 0.002** 37.93％ Example 2 0.78 0.04 0.001** 46.21％ Example 3 0.88 0.01 0.001** 39.31％ Comparative Example 1 0.98 0.04 0.002** 32.41％

[0119] Compared with the negative control, the sample groups of Examples 1-3 significantly upregulated the expression of the β-catenin gene, while the sample group of Comparative Example 1 had no significant upregulation effect. The β-catenin gene expression results of some sample groups are shown in Table 5.

[0120] Table 5

[0121] Group Mean SD P-value Improvement rate BC 1.00 0.07 / / NC 0.67 0.06 0.003## / PC 1.07 0.09 0.003** / Example 1 0.79 0.03 0.027* 17.91％ Example 2 0.86 0.05 0.014* 28.36％ Example 3 0.81 0.04 0.027* 20.90％ Comparative Example 1 0.62 0.06 0.325 /

[0122] According to the above results, compared with the sample groups of Comparative Examples 1-6, Examples 1-7 have a higher promoting effect on hair follicle growth factor (VEGF) and a higher inhibitory effect on hair follicle inhibitory factors (TGF-β, DKK1), indicating that the thiotaurine, nicotinamide, and glycine-histidine-lysine-copper in the example samples have a synergistic effect on promoting hair follicle growth factor and inhibiting hair follicle inhibitory factors. Therefore, the example sample group has a better effect in maintaining hair follicles and hair growth. By measuring the gene expression results of the hair follicle cycle protein β-catenin, the test model treated with the example sample group showed high expression of β-catenin, which has a positive effect on maintaining the hair follicle growth cycle. At the same time, the example samples can promote the growth of hair papilla cells.

[0123] The technical features of the above-mentioned embodiments can be combined arbitrarily. In order to make the description concise, not all possible combinations of the technical features in the above-mentioned embodiments are described. However, as long as there is no contradiction in the combination of these technical features, they should be considered to be within the scope of this specification.

[0124] The above-described embodiments merely represent several implementation methods of the present application. While the descriptions are relatively specific and detailed, they should not be construed as limiting the scope of the present invention. It should be noted that a person skilled in the art could make various modifications and improvements without departing from the spirit of the present application, all of which fall within the scope of protection of the present application. Therefore, the scope of protection of the present patent application shall be determined by the appended claims, and the specification may be used to interpret the content of the claims.

Claims

1. A composition, characterized in that The invention comprises the following components in parts by weight: 0.00001-10 parts of thiotaurine, 0.00001-30 parts of nicotinamide and 0.00001-10 parts of glycine-histidine-lysine-copper.

2. The composition according to claim 1, characterized in that The invention comprises the following components in parts by weight: 0.3-1 parts of thiotaurine, 1-2.5 parts of nicotinamide and 0.2-1 parts of glycine-histidine-lysine-copper; Preferably, 0.4-0.7 parts of thiotaurine, 1.3-2 parts of nicotinamide and 0.3-0.8 parts of glycine-histidine-lysine-copper; More preferably, 0.4-0.6 parts of thiotaurine, 1.4-1.7 parts of nicotinamide and 0.4-0.6 parts of glycine-histidine-lysine-copper are used.

3. The composition according to claim 1 or 2, characterized in that It also includes preservatives; Optionally, the preservative includes one or more of phenoxyethanol, methylparaben, ethylparaben, propylparaben, methylisothiazolinone, p-hydroxyacetophenone, polyol preservatives, organic acid preservatives and cationic preservatives; Optionally, the polyol preservative includes one or more of glycerol, propylene glycol, butylene glycol, 1,2-pentanediol, caprylyl glycol, ethylene glycol and 1,2-hexanediol; Optionally, the organic acid preservative includes one or more of caprylhydroxamic acid, sorbic acid and benzoic acid; Optionally, the cationic preservative includes one or more of quaternary ammonium salts and hexamidine di(hydroxyethylsulfonic acid) salt; Optionally, the composition comprises 0.1-20 parts of the preservative by weight.

4. The method for preparing the composition according to any one of claims 1 to 3, characterized in that: The method comprises the step of mixing the thiotaurine, the nicotinamide and the glycine-histidine-lysine-copper.

5. Use of the composition according to any one of claims 1 to 3 in preparing a product for promoting the proliferation of dermal papilla cells.

6. Use of the composition according to any one of claims 1 to 3 in the preparation of a product for promoting the expression or activity of hair follicle growth factor; Optionally, the hair follicle growth factor comprises VEGF.

7. Use of the composition according to any one of claims 1 to 3 in the preparation of a product for inhibiting the expression or activity of hair follicle inhibitory factor; Optionally, the hair follicle inhibitory factor includes TGF-β and / or DKK1.

8. Use of the composition according to any one of claims 1 to 3 in the preparation of a product for promoting the expression or activity of hair follicle cyclin β-catenin.

9. Use of the composition according to any one of claims 1 to 3 in preparing products for scalp care and / or hair loss prevention and growth.

10. A product, characterized in that The product comprises the composition of any one of claims 1 to 3; Optionally, the product further comprises auxiliary materials acceptable for toiletries; Optionally, the product includes toiletries.

Images